Search results for "Platelet Adhesiveness"

showing 10 items of 11 documents

Abacavir induces platelet-endothelium interactions by interfering with purinergic signalling: A step from inflammation to thrombosis.

2017

The controversy connecting Abacavir (ABC) with cardiovascular disease has been fuelled by the lack of a credible mechanism of action. ABC shares structural similarities with endogenous purines, signalling molecules capable of triggering prothrombotic/proinflammatory programmes. Platelets are leading actors in the process of thrombosis. Our study addresses the effects of ABC on interactions between platelets and other vascular cells, while exploring the adhesion molecules implicated and the potential interference with the purinergic signalling pathway. The effects of ABC on platelet aggregation and platelet-endothelium interactions were evaluated, respectively, with an aggregometer and a flo…

0301 basic medicineBlood PlateletsEndotheliumPlatelet AggregationAnti-HIV AgentsInflammationPharmacologyBiologyProinflammatory cytokine03 medical and health sciences0302 clinical medicinePlatelet Adhesivenessplatelet-endothelium interactionsVirologymedicineHumansPlatelet030212 general & internal medicinePlatelet activationPharmacologyInflammationCell adhesion moleculePurinergic receptorDeoxyguanine NucleotidesThrombosisPurinergic signallingIntercellular Adhesion Molecule-1Platelet ActivationAbacavirNRTIsDideoxynucleosidesCell biologycardiovascular diseasesP-Selectin030104 developmental biologymedicine.anatomical_structureCardiovascular DiseasesPurinesEndothelium Vascularmedicine.symptomSignal TransductionAntiviral research
researchProduct

CX3CR1/CX3CL1 Axis Mediates Platelet–Leukocyte Adhesion to Arterial Endothelium in Younger Patients with a History of Idiopathic Deep Vein Thrombosis

2018

AbstractMechanisms linking deep vein thrombosis (DVT) and subclinical atherosclerosis and risk of cardiovascular events are poorly understood. The aim of this study was to investigate the potential impact of CX3CR1/CX3CL1 axis in DVT-associated endothelial dysfunction. The study included 22 patients (age: 37.5 ± 8.2 years) with a history of idiopathic DVT and without known cardiovascular risk factors and 23 aged-matched control subjects (age: 34 ± 7.8 years). Flow cytometry was used to evaluate peripheral markers of platelet activation, leukocyte immunophenotypes and CX3CR1/CX3CL1 expression in both groups. A flow chamber assay was employed to measure leukocyte arrest under dynamic conditio…

AdultMale0301 basic medicinePathologymedicine.medical_specialtyAdolescentEndotheliumCX3C Chemokine Receptor 1InflammationComorbidity030204 cardiovascular system & hematologyMonocytesImmunophenotypingYoung Adult03 medical and health sciencesPlatelet Adhesiveness0302 clinical medicineRisk FactorsPlatelet adhesivenessHuman Umbilical Vein Endothelial CellsLeukocytesmedicineHumansPlateletLymphocytescardiovascular diseasesPlatelet activationEndothelial dysfunctionSistema cardiovascularInflammationVenous ThrombosisChemokine CX3CL1Tumor Necrosis Factor-alphabusiness.industryEndothelial CellsHematologyMiddle AgedPlatelet Activationmedicine.diseaseThrombosis030104 developmental biologymedicine.anatomical_structureMicroscopy FluorescenceCase-Control StudiesFemaleEndothelium Vascularmedicine.symptombusinessPlatelet factor 4Thrombosis and Haemostasis
researchProduct

2015

Patients suffering from chronic inflammatory diseases have an increased mortality risk resulting from cardiovascular disorders due to enhanced atherosclerotic and thrombotic events. Until now, it is not completely understood in which way an abnormal expression of pro-inflammatory mediators contributes to this elevated cardiovascular risk, but there is a need for new drugs that on the one hand suppress the expression of pro-inflammatory mediators and on the other hand inhibit arterial platelet adhesion. Thus, we analyzed the anti-inflammatory and anti-thrombotic capacity of the fungal metabolite Galiellalactone in atherosclerosis-prone apolipoprotein E-deficient mice. Treatment of the mice w…

Apolipoprotein EAortaMultidisciplinaryApolipoprotein Bbiologymedicine.drug_classbusiness.industryInflammationAnti-inflammatorymedicine.arteryPlatelet adhesivenessImmunologybiology.proteinmedicinePlateletmedicine.symptombusinessFibrinolytic agentPLOS ONE
researchProduct

A biostable, anti-fouling zwitterionic polyurethane-urea based on PDMS for use in blood-contacting medical devices.

2020

Polydimethylsiloxane (PDMS) is commonly used in medical devices because it is non-toxic and stable against oxidative stress. Relatively high blood platelet adhesion and the need for chemical crosslinking through curing, however, limit its utility. In this research, a biostable PDMS-based polyurethane-urea bearing zwitterion sulfobetaine (PDMS-SB-UU) was synthesized for potential use in the fabrication or coating of blood-contacting devices, such as a conduits, artificial lungs, and microfluidic devices. The chemical structure and physical properties of synthesized PDMS-SB-UU were confirmed by (1)H-nuclear magnetic resonance ((1)H-NMR), X-ray diffraction (XRD), and uniaxial stress-strain cur…

Blood PlateletsBiofoulingChemical structurePolyurethanesBiomedical Engineering02 engineering and technologymacromolecular substancesengineering.material010402 general chemistry01 natural sciencesHemolysisArticlechemistry.chemical_compoundPlatelet AdhesivenessCoatingCoated Materials BiocompatiblemedicineAnimalsGeneral Materials ScienceDimethylpolysiloxanesCuring (chemistry)PolyurethaneSheepPolydimethylsiloxaneChemistrytechnology industry and agricultureFibrinogenGeneral ChemistryGeneral Medicine021001 nanoscience & nanotechnologymedicine.diseaseHemolysisElectrospinning0104 chemical sciencesRatsQuaternary Ammonium CompoundsChemical engineeringengineeringUreaAdsorptionSulfonic Acids0210 nano-technologyJournal of materials chemistry. B
researchProduct

Platelet-endothelial interaction in tumor angiogenesis and microcirculation

2003

Activated platelets release angiogenic growth factors and have therefore been proposed to contribute to tumor angiogenesis within a potentially prothrombotic tumor microcirculation. The aim of the study was to investigate interactions of platelets with the angiogenic microvascular endothelium of highly vascularized solid tumors during growth and in response to endothelial stimulation in comparison with normal subcutaneous tissue. Experiments were performed in the dorsal skinfold chamber preparation of C57BL/6J mice bearing the Lewis lung carcinoma (LLC-1) or methylcholanthrene-induced fibrosarcoma (BFS-1). Fluorescently labeled rolling and adherent platelets, red blood cell velocity, and ve…

Blood PlateletsMalemedicine.medical_specialtyEndotheliumAngiogenesisFibrosarcomaImmunologyBiologyBiochemistrySkin Window TechniqueNeovascularizationCarcinoma Lewis LungMicePlatelet AdhesivenessCell MovementPlatelet adhesivenessInternal medicinemedicineAnimalsPlateletPlatelet activationCalcimycinIonophoresNeovascularization PathologicMicrocirculationVideotape RecordingLewis lung carcinomaCell BiologyHematologyPlatelet ActivationMice Inbred C57BLEndothelial stem cellmedicine.anatomical_structureEndocrinologyImmunologyCalciumEndothelium Vascularmedicine.symptomBlood Flow VelocityMethylcholanthreneBlood
researchProduct

Targeted SERPIN (TaSER): A dual‐action antithrombotic agent that targets platelets for SERPIN delivery

2021

BACKGROUND Occlusive thrombi are not homogeneous in composition. The core of a thrombus is rich in activated platelets and fibrin while the outer shell contains resting platelets. This core is inaccessible to plasma proteins. We produced a fusion protein (targeted SERPIN-TaSER), consisting of a function-blocking VH H against glycoprotein Ibα (GPIbα) and a thrombin-inhibiting serine protease inhibitor (SERPIN; α1-antitrypsin 355 AIAR358 ) to interfere with platelet-driven thrombin formation. AIM To evaluate the antithrombotic properties of TaSER. METHODS Besides TaSER, we generated three analogous control variants with either a wild-type antitrypsin subunit, a non-targeting control VH H, or …

Blood PlateletsbiologyChemistryHematologySerpinFibrinCell biologyTissue factorPlatelet AdhesivenessThrombinFibrinolytic AgentsVon Willebrand factorvon Willebrand FactorAntithromboticmedicinebiology.proteinHumansPlateletPlatelet activationSerpinscirculatory and respiratory physiologymedicine.drugJournal of Thrombosis and Haemostasis
researchProduct

Inhibition of Platelet Aggregation Caused by Estrogen Treatment in Patients with Carcinoma of the Prostate

1975

Platelet aggregation is increased in patients with carcinoma of the prostate treated with estrogens. Hence, these patients have a high incidence of cardiovascular and thromboembolic diseases. Platelet aggregation has been tested with the platelet aggregation test. It was inhibited by administration of 500 mg. acetylsalicylic acid twice daily. An aggregation inhibiting effect has been found in all 38 patients. To reduce the excess hazards of cardiovascular complications of estrogens in treating carcinoma of the prostate acetylsalicylic acid is recommended as an adjunct therapy.Estrogen therapy for prostatic carcinoma may lead to the development of cardiovascular complications, such as thromb…

Malemedicine.medical_specialtyPlatelet Aggregationmedicine.drug_classUrologyPopulationPharmacologyPlatelet AdhesivenessProstateInternal medicineCarcinomaHumansEndocrine systemMedicineCastrationeducationDiethylstilbestroleducation.field_of_studyAspirinEstradiolbusiness.industryGenitourinary systemProstatic NeoplasmsCancerEstrogensmedicine.diseaseEndocrinologymedicine.anatomical_structureEstrogenbusinessHormoneJournal of Urology
researchProduct

Modification of human platelet adhesion on biomaterial surfaces by protein preadsorption under static and flow conditions.

2004

Biomaterial-induced thrombosis remains one of the main complications of vascular implant devices. Preadsorbed proteins on the biomaterial/blood interface will modify the adhesion and activation of platelets (PTLs) during the initial contact-phase. Our results clearly show that PTL-adherence on biomaterials is influenced not only by protein preadsorption, but also by flow conditions. The covalent coating of TCPS and glass by phosphorylcholine (PC) induces a significant decrease of PTL adhesion but leads to a slight, but nevertheless significant activation of PTL, which was detected by the induction of P-selectin expression using FACS analysis. Methodologically, the visualization of PTL adhes…

Materials scienceBiomedical EngineeringBiophysicschemistry.chemical_elementBioengineeringBiocompatible MaterialsCalciumIn Vitro TechniquesBiomaterialsBlood cellPlatelet AdhesivenessIn vivoMaterials TestingmedicineHumansPlateletPhosphorylcholineBiomaterialThrombosisAdhesionBlood ProteinsFlow CytometryPlatelet ActivationBiomechanical PhenomenaBlood Vessel ProsthesisP-Selectinmedicine.anatomical_structurechemistryembryonic structuresImmunologyHemorheologyBiophysicsAdsorptionProtein adsorptionJournal of materials science. Materials in medicine
researchProduct

A critical evaluation of caplacizumab for the treatment of acquired thrombotic thrombocytopenic purpura

2020

Introduction: Acquired thrombotic thrombocytopenic purpura (aTTP) is a thrombotic microangiopathy caused by inhibitory autoantibodies against ADAMTS13 protein. Until recently, the combination of plasma exchange (PEX) and immunosuppression has been the standard front-line treatment in this disorder. However, aTTP-related mortality, refractoriness, and relapse are still a matter of concern. Areas covered: The better understanding of the pathophysiological mechanisms of aTTP has allowed substantial improvements in the diagnosis and treatment of this disease. Recently, the novel anti-VWF nanobody caplacizumab has been approved for acute episodes of aTTP. Caplacizumab is capable to block the adh…

Thrombotic microangiopathyExacerbationvirusesmedicine.medical_treatmentADAMTS13 ProteinDiseaseBioinformaticsAutoantigens03 medical and health sciencesPlatelet Adhesiveness0302 clinical medicineFibrinolytic AgentsProtein DomainsCrotalid Venomsvon Willebrand FactormedicineHumansImmunologic FactorsMulticenter Studies as TopicLectins C-TypeMolecular Targeted TherapyDrug ApprovalClinical Trials as TopicAcquired Thrombotic Thrombocytopenic PurpuraPlasma ExchangePurpura Thrombotic Thrombocytopenicbusiness.industryStandard treatmentfungiImmunosuppressionDrugs InvestigationalHematologyAptamers NucleotideSingle-Domain Antibodiesbiochemical phenomena metabolism and nutritionmedicine.diseaseCombined Modality TherapyRecombinant ProteinsADAMTS13AcetylcysteineTreatment Outcome030220 oncology & carcinogenesisDrug Therapy CombinationCaplacizumabbusinessImmunosuppressive Agents030215 immunologyExpert Review of Hematology
researchProduct

Platelet Function Tests and Coronary Heart Disease

1984

It is well known that the formation of a platelet aggregate is the first step in an arterial thrombotic process.

medicine.medical_specialtyFramingham Risk ScoreEndotheliumPlatelet aggregationbusiness.industryeducationmedicine.diseaseCoronary heart diseasestomatognathic diseasesmedicine.anatomical_structurePlatelet function testPlatelet adhesivenessInternal medicinemedicineCardiologyPlateletMyocardial infarctionbusiness
researchProduct